Trial ID 21235 | Maryland Oncology Hematology Trial ID 21235 – Maryland Oncology Hematology

Trial ID 21235

Trial Information - Phase III

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma

Protocol ID: CNIS793B12301

Sponsor: Novartis Pharmaceuticals Corporation

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Pancreas

Investigator

Juneja MD, Vinni

Status

OPEN TO ENROLLMENT

Sponsor

Novartis Pharmaceuticals Corporation

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology